Lead Product(s): PTH(1-34)
Therapeutic Area: Endocrinology Product Name: PTH(1-34)
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2020
The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.
Lead Product(s): PLX038,Rucaparib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
First patient was treated with its PLX038 in a Phase 1B trial for small-cell lung cancer. The trial combines long-acting PEGylated SN-38, PLX038, with the Clovis Oncology PARP inhibitor, rucaparib.